A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours

Wilson, A.; Fox, H. Herbert; Scott, Ian; Lee, H.; Dent, Maria F.; Golding, P R

doi:10.1038/bjc.1991.21

Cited by 19 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 6 of our 36 ascites samples had detectable TGF-· levels. Arteaga et al [10] showed that 42% of their ovarian cancer patients' effusions (approximately 25% of the samples were pleural fluid) had detectable TGF-· by RIA, while Wilson et al [19] could find no TGF-· in any of their ascites samples. TGF-· is initially translated as a 160-amino acid trans-membrane precursor which then undergoes proteolytic cleavage by a sequence-specific protease found external to the cell membrane releasing the 50-amino acid TGF-·.…”

Section: Discussionmentioning

confidence: 99%

Transforming Growth Factor-Alpha Levels in the Serum and Ascites of Patients withAdv anced Epithelial Ovarian Cancer

Saltzman¹,

Hartenbach²,

Carter³

et al. 1999

Gynecol Obstet Invest

View full text Add to dashboard Cite

A variety of cytokines have been identified to play a role in ovarian cancer. In this pilot study, we sought to determine whether transforming growth factor-α (TGF-α) was detectable in the serum and ascites of women with advanced stage epithelial ovarian cancer. TGF-α was measured using an enzyme-linked immunosorbent assay and was present in 18 of 25 control sera. Prior to treatment for stage III or IV epithelial ovarian cancer, 18 patients had undetectable serum levels of TGF-α, while 18 had values ranging from 10.6 to 531.7 pg/ml. The group with undetectable levels had a 6-month greater median survival; detectable TGF-α might be a negative prognostic indicator. In a separate group undergoing second-look laparotomy, differences in median TGF-α values versus controls and the primary study group approached significance. TGF-α was detected in significantly more control peritoneal fluid samples than in patient ascites. A larger study is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Transforming Growth Factor-Alpha Levels in the Serum and Ascites of Patients withAdv anced Epithelial Ovarian Cancer

Saltzman¹,

Hartenbach²,

Carter³

et al. 1999

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Cystic fluid production takes part in both malignant and benign pathologies of ovary. These fluids have been shown to contain factors that influence the growth of ovarian carcinoma cells and the transformation of mesothelial cells ( 19 ) . HGF is known to be produced by mesenchymal originated cells and effects the neighboring epithelial originated cells.…”

mentioning

confidence: 99%

Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts

Baykal¹,

Demirtaş²,

Al³

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

Hepatocyte growth factor (HGF) is known to take role in oncogenesis and tumoral behavior of the tumors of the organs that contain mesenchymal and epithelial cells together. This study aims to compare HGF levels in cyst fluids of epithelial ovarian cancer and benign ovarian cysts and look for the role of HGF in ovarian carcinogenesis. Twenty-four consecutive patients with ovarian cancer and 34 with benign cysts of ovary were recruited prospectively at Gynecologic Oncology Departments of SSK Ankara Maternity Hospital and Hacettepe University School of Medicine between 2001 and 2002. Cyst fluids were collected during primary staging in cancer patients and during laparatomy for benign patients. HGF levels were measured by enzyme-linked immunosorbent assay method. Median HGF levels of the benign ovarian cysts and epithelial ovarian tumoral fluids were found as 3822 pg/ml (85-15,253 pgr/ml) and 12,962 pgr/ml (4136-16,025 pgr/ml), respectively. Malign cyst fluids have higher HGF levels when compared with benign ovarian cysts (P < 0.01). This finding suggests that HGF may take a paracrine role in oncogenic differentiation and tumoral development of epithelial ovarian cancers. Mechanisms that take role in HGF secretion and the answers of the neighboring epithelial cells to HGF during tumoral development need to be investigated.

show abstract

“…An unknown growth factor has been postulated to be responsible for the elevated growth‐stimulating activity on the ovarian carcinoma cell line HEY in the ascitic fluids of ovarian carcinoma patients, but not those of patients with other gynecologic carcinoma or benign ovarian tumors 1. The activity that transforms mesothelial cells in ascites, cyst fluids, and peritoneal fluids in patients with ovarian malignancy, benign diseases, and non‐tumor‐related gynecological conditions were compared, and the elevated activity was found to be tumor‐associated 2. The active principle in the former was later identified as lysophosphatidic acid (LPA),3 but the structure of the active principle in the latter remains obscure.…”

mentioning

confidence: 99%

Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors

Tokumura

Tominaga

Yasuda

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND Several studies have shown that lysophosphatidic acid (LPA), a phospholipidic chemical mediator, is relevant to the pathogenesis of ovarian carcinoma. Higher plasma levels of LPA have been reported in patients with ovarian carcinoma than in healthy patients, and LPA is known to activate ovarian carcinoma cells. To determine the reason for the increased plasma LPA levels in ovarian carcinoma patients, we compared the activities of serum lysophospholipase D, a novel LPA‐producing metallo‐enzyme, in healthy volunteers, patients with benign ovarian tumor, and patients with ovarian carcinoma. METHODS Lysophospholipase D activity was assessed by measuring the percentage conversion of [14C]palmitoyl‐lysophosphatidylcholine (LPC) added to human serum. The apparent enzyme activities were corrected based on the serum levels of palmitoyl‐LPC determined by gas‐liquid chromatography after its purification and conversion to fatty acid methyl esters. RESULTS The apparent activity of lysophospholipase D in serum preparations from four patients with ovarian carcinoma at Stage IV was significantly higher than those from five healthy subjects, five patients with benign ovarian tumors, and fourteen patients with ovarian carcinoma at Stages I (n = 5), II (n = 4), and III (n = 5). The serum levels of LPC, an endogenous substrate of lysophospholipase D, in ovarian carcinoma patients were less than those in patients with benign ovarian tumors. There were no significant differences in the corrected lysophospholipase D activity for the LPC levels in healthy women, patients with benign ovarian tumors, and patients with ovarian carcinoma at various stages. CONCLUSIONS The current results suggest that lysophospholipase D is not associated with the elevated plasma levels of LPA in ovarian carcinoma patients previously reported, although only a limited number of patients were analyzed. Cancer 2002;94:141–51. © 2002 American Cancer Society.

show abstract

A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours

Cited by 19 publications

References 22 publications

Transforming Growth Factor-Alpha Levels in the Serum and Ascites of Patients withAdv anced Epithelial Ovarian Cancer

Transforming Growth Factor-Alpha Levels in the Serum and Ascites of Patients withAdv anced Epithelial Ovarian Cancer

Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts

Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors

Contact Info

Product

Resources

About